PDS Biotechnology Corporation (PDSB) concluded trading on Thursday at a closing price of $1.57, with 0.54 million shares of worth about $0.85 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -21.50% during that period and on May 22, 2025 the price saw a loss of about -0.63%. Currently the company’s common shares owned by public are about 45.45M shares, out of which, 43.98M shares are available for trading.
Stock saw a price change of 16.30% in past 5 days and over the past one month there was a price change of 27.64%. Year-to-date (YTD), PDSB shares are showing a performance of -3.68% which decreased to -53.55% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.85 but also hit the highest price of $4.42 during that period. The average intraday trading volume for PDS Biotechnology Corporation shares is 656.76K. The stock is currently trading 17.08% above its 20-day simple moving average (SMA20), while that difference is up 26.68% for SMA50 and it goes to -25.73% lower than SMA200.
PDS Biotechnology Corporation (NASDAQ: PDSB) currently have 45.45M outstanding shares and institutions hold larger chunk of about 17.85% of that.
The stock has a current market capitalization of $71.76M and its 3Y-monthly beta is at 1.32. It has posted earnings per share of -$0.94 in the same period. It has Quick Ratio of 2.33 while making debt-to-equity ratio of 0.85. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for PDSB, volatility over the week remained 6.16% while standing at 5.43% over the month.
Analysts are in expectations that PDS Biotechnology Corporation (PDSB) stock would likely to be making an EPS of -0.22 in the current quarter, while forecast for next quarter EPS is -0.21 and it is -0.85 for next year. For the current quarter EPS, analysts have given the company a lowest target -0.23 which is -0.22 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -0.23 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 17.15% while it is estimated to increase by 0.39% in next year. EPS is likely to grow at an annualized rate of 6.45% for next 5-years, compared to annual growth of 6.42% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by B. Riley Securities on November 01, 2022 offering a Buy rating for the stock and assigned a target price of $10 to it. Coverage by Cantor Fitzgerald stated PDS Biotechnology Corporation (PDSB) stock as an Overweight in their note to investors on June 28, 2021, suggesting a price target of $25 for the stock. On November 10, 2020, H.C. Wainwright Upgrade their recommendations, while on May 27, 2020, Alliance Global Partners Initiated their ratings for the stock with a price target of $4. Stock get an Outperform rating from Noble Capital Markets on March 09, 2020.
